Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-β

Cardiovascular Therapeutics

Volumn 30, Issue 1, 2012, Pages

  Edgley, Amanda J ^a   Krum, Henry ^b   Kelly, Darren J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cardiac remodeling; Fibrosis; Heart failure; Transforming growth factor

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ETANERCEPT; FT 011; MATRIX METALLOPROTEINASE; MINERALOCORTICOID ANTAGONIST; PIRFENIDONE; PLACEBO; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANOREXIA; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; DIABETIC CARDIOMYOPATHY; DRUG TARGETING; DYSPEPSIA; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; LUNG FIBROSIS; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; VOMITING;

ANIMALS; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; MYOCARDIUM; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 84856259347     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00228.x     Document Type: Review

References (139)

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181.
2. AIHW. Heart Failure: What of the future? Canberra: Australian Institute of Health and Welfare, 2003.
3. Najafi F, Jamrozik K, Dobson AJ. Understanding the 'epidemic of heart failure': A systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009;11:472-479.
4. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582.
5. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-262.
6. Chatterjee K, Massie B. Systolic and diastolic heart failure: Differences and similarities. J Card Fail 2007;13:569-576.
7. Konstam MA. "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. J Card Fail 2003;9:1-3.
8. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: A credible surrogate endpoint. J Card Fail 2003;9:350-353.
9. Inesi G, Prasad AM, Pilankatta R. The Ca2+ ATPase of cardiac sarcoplasmic reticulum: Physiological role and relevance to diseases. Biochem Biophys Res Commun 2008;369:182-187.
10. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
11. Borbely A, Papp Z, Edes I, Paulus WJ. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep 2009;61:139-145.
12. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279-292.
13. Barasch E, Gottdiener JS, Aurigemma G, Kitzman DW, Han J, Kop WJ, et al. Association between elevated fibrosis markers and heart failure in the elderly: The cardiovascular health study. Circ Heart Fail 2009;2:303-310.
14. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: Evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888-895.
15. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: The renaissance cell. Circ Res 2009;105:1164-1176.
16. Kawaguchi M, Techigawara M, Ishihata T, Asakura T, Saito F, Maehara K, et al. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels 1997;12:267-274.
17. Mays PK, Bishop JE, Laurent GJ. Age-related changes in the proportion of types I and III collagen. Mech Ageing Dev 1988;45:203-212.
18. Mukherjee D, Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin Invest. 1991;88:1141-1146.
19. Mukherjee D, Sen S. Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: Role of blood pressure. J Mol Cell Cardiol 1993;25:185-196.
20. Nunoda S, Genda A, Sugihara N, Nakayama A, Mizuno S, Takeda R. Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels 1985;1:43-47.
21. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977;60:884-899.
22. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972;30:595-602.
23. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999;99:2750-2756.
24. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-855.
25. Sun Y. Myocardial repair/remodelling following infarction: Roles of local factors. Cardiovasc Res 2009;81:482-490.
26. Frustaci A, Loperfido F, Pennestri F. Hypertrophic cardiomyopathy simulating an infiltrative myocardial disease. Br Heart J 1985;54:329-332.
27. Wolk R, Cobbe SM, Hicks MN, Kane KA. Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: Implications for arrhythmogenesis and anti-arrhythmic drug therapy. Pharmacol Ther 1999;84:207-231.
28. Diez J, Lopez B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001;16:328-335.
29. Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222-1226.
30. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995;75:913-918.
31. Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 2003;285:H2587-H2591.
32. Norton GR, Tsotetsi J, Trifunovic B, Hartford C, Candy GP, Woodiwiss AJ. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 1997;96:1991-1998.
33. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001;103:155-160.
34. Avendano GF, Agarwal RK, Bashey RI, Lyons MM, Soni BJ, Jyothirmayi GN, et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999;48:1443-1447.
35. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003;419:89-96.
36. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89:151-163.
37. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol 1979;128:79-85.
38. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: Two experimental models of myocardial fibrosis. Cardiovasc Res 1990;24:741-747.
39. Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006;63:2584-2596.
40. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res 2006;98:596-605.
41. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117:568-575.
42. Young JB. The global epidemiology of heart failure. Med Clin North Am 2004;88:1135-1143, ix.
43. Krum H, Abraham WT. Heart failure. Lancet 2009;373:941-955.
44. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
46. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
47. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003;362:767-771.
48. Packer M, Poole-Wilson PA, Armstrong PW, et al. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-2318.
49. Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
50. Weber KT. From inflammation to fibrosis: A stiff stretch of highway. Hypertension 2004;43:716-719.
51. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007;152:1042-1048.
52. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001;37(2 Part 2):787-793.
53. Kuwahara F, Kai H, Tokuda K, Niiyama H, Tahara N, Kusaba K, et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 2003;41(3 Pt 2):819-823.
54. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, et al. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 2007;25:455-461.
55. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007;75:29-39.
56. Tokuda K, Kai H, Kuwahara F, Imaizumi T. Sub-depressor dose of angiotensin type-1 receptor blocker inhibits transforming growth factor-beta-mediated perivascular fibrosis in hypertensive rat hearts. J Cardiovasc Pharmacol 2003;42(Suppl 1):S61-S65.
57. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001;104:2716-2721.
58. Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995;30:537-543.
59. Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994;74:727-739.
60. Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol 1997;29:31-42.
61. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345.
62. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2009;359:2456-2467.
63. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial. Lancet 2007;369:2079-2087.
64. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003;362:777-781.
65. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-2479.
66. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009;54:1674-1682.
67. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone. N Engl J Med 1999;341:709-717.
68. Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, et al. Randomized, double blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010;3:347-353.
69. Zannad F, Alla F, Dousset B, Perez A, Pitt B; Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Circulation 2000;102:2700-2706.
70. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: The cytokine hypothesis. J Card Fail 1996;2:243-249.
71. Deswal A, Petersen NJ, Feldman AM, White BG, Mann DL. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: A report from the Vesnarinone Trial. Chest 2001;120:453-459.
72. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-2059.
73. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-3067.
74. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol 2005;95:9C-16C; discussion 38C-40C.
75. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602.
76. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3140.
77. Border WA, Noble NA. Fibrosis linked to TGF-beta in yet another disease. J Clin Invest 1995;96:655-656.
78. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003;116(Pt 2):217-224.
79. Sehgal I, Thompson TC. Novel regulation of type IV collagenase (matrix metalloproteinase-9 and -2) activities by transforming growth factor-beta1 in human prostate cancer cell lines. Mol Biol Cell 1999;10:407-416.
80. Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, et al. Matrix remodeling in experimental and human heart failure: A possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 2003;284:H626-H634.
81. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation 2003;107:984-991.
82. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-1949.
83. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
84. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: Consequences for extracellular matrix remodeling and wound healing. J Dermatol Sci 2004;35:83-92.
85. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993;122:103-111.
86. Sigel AV, Centrella M, Eghbali-Webb M. Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-beta 1. J Mol Cell Cardiol 1996;28:1921-1929.
87. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, et al. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors 1988;1:91-99.
88. Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990;85:507-514.
89. Li RK, Li G, Mickle DA, Weisel RD, Merante F, Luss H, et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997;96:874-881.
90. Elsasser A, Decker E, Kostin S, Hein S, Skwara W, Muller KD, et al. A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium. Mol Cell Biochem 2000;213:17-28.
91. Fukumoto H, Naito Z, Asano G, Aramaki T. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb 1998;5:29-35.
92. Boyle AJ, Kelly DJ, Zhang Y, Cox AJ, Gow RM, Way K, et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 2005;39:213-221.
93. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, et al. Inhibition of protein kinase C2 by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circul Heart Failure 2009;2:129-137.
94. Wunsch M, Sharma HS, Markert T, Bernotat-Danielowski S, Schott RJ, Kremer P, et al. In situ localization of transforming growth factor beta 1 in porcine heart: Enhanced expression after chronic coronary artery constriction. J Mol Cell Cardiol 1991;23:1051-1062.
95. Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992;262(6 Pt 2):H1861-H1866.
96. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: Role of transforming growth factor-beta. Cardiovasc Res 2005;65:694-701.
97. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: The role of angiotensin type 1 receptor antagonism. Diabetes 2007;56:641-646.
98. Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2010;298:H1415-H1425.
99. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007;76:280-291.
100. Bonnet F, Cao Z, Cooper ME, Cox AJ, Kelly DJ, Gilbert RE. Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes. Diabetes Metab 2003;29(4 Pt 1):386-392.
101. Jones SE, Gilbert RE, Kelly DJ. Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes. J Diabetes Complications 2004;18:309-315.
102. Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, Krum H, et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2007;293:H2860-H2869.
103. Kelly DJ, Zhang Y, Cox AJ, Gilbert RE. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int 2006;69:1954-1960.
104. Kelly DJ, Zhang Y, Gow R, Gilbert RE. Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004;15:2619-2629.
105. Mifsud S, Kelly DJ, Qi W, Zhang Y, Pollock CA, Wilkinson-Berka JL, et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003;95:p83-p91.
106. Tokuyama H, Kelly DJ, Cox A, Zhang Y, Thai K, Nikolic-Paterson DJ, et al. Tranilast ameliorates experimental mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 2008;109:e1-e7.
107. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 2008;103:485-492.
108. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, et al. Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 2004;64:526-535.
109. Ellmers LJ, Scott NJ, Medicherla S, Pilbrow AP, Bridgman PG, Yandle TG, et al. Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 2008;149:5828-5834.
110. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, et al. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 2005;111:2430-2437.
111. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106:130-135.
112. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, et al. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998;32:273-279.
113. Frazier K, Thomas R, Scicchitano M, Mirabile R, Boyce R, Zimmerman D, et al. Inhibition of ALK5 signaling induces physeal dysplasia in rats. Toxicol Pathol 2007;35:284-295.
114. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001;44:474-480.
115. Lin SL, Chen RH, Chen YM, Chiang WC, Tsai TJ, Hsieh BS. Pentoxifylline inhibits platelet-derived growth factor-stimulated cyclin D1 expression in mesangial cells by blocking Akt membrane translocation. Mol Pharmacol 2003;64:811-822.
116. Miyazawa N, Umemura K, Kondo K, Nakashima M. Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat. J Cardiovasc Pharmacol 1997;30:157-162.
117. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-218.
118. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995;125:779-785.
119. Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl 1997;63:S239-S243.
120. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998;54:99-109.
121. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
122. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Int Med 2002;41:1118-1123.
123. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159(4 Pt 1):1061-1069.
124. Lee KW, Everett THt, Rahmutula D, Guerra JM, Wilson E, Ding C, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006;114:1703-1712.
125. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001;133:687-694.
126. Mirkovic S, Seymour AM, Fenning A, Strachan A, Margolin SB, Taylor SM, et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br J Pharmacol 2002;135:961-968.
127. Qi W, Chen X, Twigg S, Polhill TS, Gilbert RE, Pollock CA. Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells. Kidney Int 2006;69:989-995.
128. Hocher B, Godes M, Olivier J, Weil J, Eschenhagen T, Slowinski T, et al. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens 2002;20:745-451.
129. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. J Hypertens 2004;22:1007-1015.
130. Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Kossamehl P, Hocher B, et al. Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat. Hypertension 2000;36:747-754.
131. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, et al. Results of prevention of REStenosis with tranilast and its outcomes (PRESTO) trial. Circulation 2002;106:1243-1250.
132. Zammit SC, Cox AJ, Gow RM, Zhang Y, Gilbert RE, Krum H, et al. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. Bioorg Med Chem Lett 2009;19:7003-7006.
133. Elsik M, Zhang Y, Wang B, Kompa A, Gilbert RE, Krum H, et al. Improvement in left ventricular function due to a reduction of myocardial fibrosis following myocardial infarction using a purpose designed novel anti fibrotic drug FT-011. Circulation 2007;116:101.
134. Zhang YT, Williams S, Zammit S, Krum H, Gilbert RE, Kelly DJ. FT011, A novel synthetic anti-fibrotic drug attenuates fibrosis and proteinuria in advanced experimental diabetic nephropathy. Nephrology 2008;13(Suppl 3):A118-A119.
135. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, et al. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 2004;44:1679-1689.
136. Kompa AR, See F, Lewis DA, Adrahtas A, Cantwell DM, Wang BH, et al. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther 2008;325:741-750.
137. Clark JE, Sarafraz N, Marber MS. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. Pharmacol Ther 2007;116:192-206.
138. Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: Association with changes in MAPK pathways. Am J Physiol Heart Circ Physiol 2003;285:H822-H832.
139. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: Mechanisms and signal transduction pathways. Cardiovasc Res 2000;47:23-37.